AUSTIN, Texas – Entering the Investigational Phase in the race to develop a vaccine for the SARS-CoV-2 or COVID vaccine, Tekton Research is in search of participants who have not been diagnosed with the novel Coronavirus to join an important study.
“Now is the time to help take the fight to COVID’s front door. You can make a difference in your community, in your country, and across the globe by enrolling today,” said Kip McKenzie- Tekton Research Founder/CEO.
As research progresses Tekton is encouraging people over the age of 18 who have not received a positive diagnosis for COVID-19 to apply for their latest round of studies on the SARS-CoV-2 virus. A large test population is needed to allow researchers to measure the efficacy of the vaccine across many different demographics since people around the globe have been affected by COVID-19. In addition to helping their respective communities fight back against this pandemic, research participants will also be compensated for their time and travel.
All research trials are regulated by the FDA and must be approved, reviewed, and monitored by institutional review boards, IRBs, whose sole purpose is to protect the rights and safety of clinical trial participants.
Tekton Research is a Texas-based, family-owned business with locations in Austin, Beaumont, San Antonio, Oklahoma, Fort Collins, and Atlanta. Tekton Research focuses on the conduct of clinical trials for pharmaceutical and device companies. Since its founding 14 years ago, Tekton has completed hundreds of clinical studies ranging from women’s health, rheumatology, dermatology, preventative medicine, and many other practice areas. Tekton has contributed to many medical advancements that have expanded treatment options for everyone.